Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros

Base de dados
Ano de publicação
Tipo de documento
Intervalo de ano de publicação
1.
Mol Ther ; 22(1): 92-101, 2014 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-24089139

RESUMO

Despite progress in identifying molecular drivers of cancer, it has been difficult to translate this knowledge into new therapies, because many of the causal proteins cannot be inhibited by conventional small molecule therapeutics. RNA interference (RNAi), which uses small RNAs to inhibit gene expression, provides a promising alternative to reach traditionally undruggable protein targets by shutting off their expression at the messenger RNA (mRNA) level. Challenges for realizing the potential of RNAi have included identifying the appropriate genes to target and achieving sufficient knockdown in tumors. We have developed high-potency Dicer-substrate short-interfering RNAs (DsiRNAs) targeting ß-catenin and delivered these in vivo using lipid nanoparticles, resulting in significant reduction of ß-catenin expression in liver cancer models. Reduction of ß-catenin strongly reduced tumor burden, alone or in combination with sorafenib and as effectively as DsiRNAs that target mitotic genes such as PLK1 and KIF11. ß-catenin knockdown also strongly reduced the expression of ß-catenin-regulated genes, including MYC, providing a potential mechanism for tumor inhibition. These results validate ß-catenin as a target for liver cancer therapy and demonstrate the promise of RNAi in general and DsiRNAs in particular for reaching traditionally undruggable cancer targets.


Assuntos
Neoplasias Hepáticas/genética , Neoplasias Hepáticas/patologia , RNA Interferente Pequeno/genética , beta Catenina/genética , Animais , Linhagem Celular Tumoral , Modelos Animais de Doenças , Expressão Gênica , Técnicas de Silenciamento de Genes , Humanos , Neoplasias Hepáticas/imunologia , Neoplasias Hepáticas/terapia , Masculino , Camundongos , Nanopartículas/administração & dosagem , Nanopartículas/química , Interferência de RNA , RNA Interferente Pequeno/química , RNA Interferente Pequeno/metabolismo , Ribonuclease III/metabolismo , Carga Tumoral/genética , Ensaios Antitumorais Modelo de Xenoenxerto , beta Catenina/metabolismo
2.
EMBO J ; 23(2): 473-82, 2004 Jan 28.
Artigo em Inglês | MEDLINE | ID: mdl-14739932

RESUMO

Dopamine-modulated behaviors, including information processing and reward, are subject to behavioral plasticity. Disruption of these behaviors is thought to support drug addictions and psychoses. The plasticity of dopamine-mediated behaviors, for example, habituation and sensitization, are not well understood at the molecular level. We show that in the nematode Caenorhabditis elegans, a D1-like dopamine receptor gene (dop-1) modulates the plasticity of mechanosensory behaviors in which dopamine had not been implicated previously. A mutant of dop-1 displayed faster habituation to nonlocalized mechanical stimulation. This phenotype was rescued by the introduction of a wild-type copy of the gene. The dop-1 gene is expressed in mechanosensory neurons, particularly the ALM and PLM neurons. Selective expression of the dop-1 gene in mechanosensory neurons using the mec-7 promoter rescues the mechanosensory deficit in dop-1 mutant animals. The tyrosine hydroxylase-deficient C. elegans mutant (cat-2) also displays these specific behavioral deficits. These observations provide genetic evidence that dopamine signaling modulates behavioral plasticity in C. elegans.


Assuntos
Proteínas de Caenorhabditis elegans/fisiologia , Caenorhabditis elegans/fisiologia , Plasticidade Neuronal , Receptores de Dopamina D1/fisiologia , Tato , Animais , Comportamento Animal , Caenorhabditis elegans/genética , Proteínas de Caenorhabditis elegans/genética , Dopamina/biossíntese , Dopamina/farmacologia , Habituação Psicofisiológica , Mutação , Neurônios Aferentes/metabolismo , Receptores de Dopamina D1/genética
SELEÇÃO DE REFERÊNCIAS
Detalhe da pesquisa